Phase I Randomized Double-Blind Study on Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LB-0702 vs. Romiplostim in Healthy Volunteers

The primary objective of this study is to compare the **pharmacokinetics** (PK), **pharmacodynamics** (PD), immunogenicity, safety, and tolerability of LB-0702 with Nplate® in healthy volunteers. This is a Phase I, randomized, consecutive dose, double-blind, parallel study. The clinical relevance of this objective lies in establishing the bioequivalence of LB-0702 to Nplate®, which is crucial for ensuring similar therapeutic effects and safety profiles in clinical use.

The clinical trial involves a study population consisting exclusively of **male** participants, with an age range categorized as adults. The sponsor has not provided the total number of participants involved in this bioequivalence study. The trial population was selected without targeting any vulnerable groups, and the study does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not disclosed specific inclusion or exclusion criteria for this trial. The study is not focused on any particular medical condition, as it is a bioequivalence study.

The clinical trial is designed as a **Phase I**, randomized, consecutive dose, double-blind, parallel study. It aims to compare the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, safety, and tolerability of LB-0702 and Nplate® in healthy volunteers. The trial is categorized as a bioequivalence study, and no specific medical condition is applicable. The estimated recruitment start date is April 15, 2025, with an anticipated end date of November 15, 2025, indicating an overall trial duration of approximately seven months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The study will include multiple follow-up visits to monitor the participants' response to the investigational products, assess safety parameters, and collect data on PK and PD profiles. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the overall outcomes and any long-term effects.

The expected length of participant involvement will span the entire trial duration, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design ensures that all procedures are conducted under strict adherence to ethical guidelines and regulatory requirements, maintaining the integrity and scientific validity of the study outcomes.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include any additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on April 15, 2025, with an estimated completion date of November 15, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments. The trial's design and execution will be aligned with regulatory requirements and scientific standards to accurately determine the efficacy of the intervention under investigation.